

EAST 10/040,319

L Number	Hits	Search Text	DB	Time stamp
1	2670	((514/234.2) or (514/234.5) or (514/249) or (514/252.17) or (514/264.1) or (514/266.2) or (514/266.21)).CCLS.	USPAT; US-PGPUB	2004/05/23 16:22
2	2021	((544/116) or (544/117) or (544/279) or (544/284) or (544/350)).CCLS.	USPAT; US-PGPUB	2004/05/23 16:23
3	3864	((514/234.2) or (514/234.5) or (514/249) or (514/252.17) or (514/264.1) or (514/266.2) or (514/266.21)).CCLS.) or ((544/116) or (544/117) or (544/279) or (544/284) or (544/350)).CCLS.)	USPAT; US-PGPUB	2004/05/23 16:23
4	592	((514/234.2) or (514/234.5) or (514/249) or (514/252.17) or (514/264.1) or (514/266.2) or (514/266.21)).CCLS.) or ((544/116) or (544/117) or (544/279) or (544/284) or (544/350)).CCLS.) and (quinazolinone or quinazolone or quinazolin)	USPAT; US-PGPUB	2004/05/23 16:24
5	545	((514/234.2) or (514/234.5) or (514/249) or (514/252.17) or (514/264.1) or (514/266.2) or (514/266.21)).CCLS.) or ((544/116) or (544/117) or (544/279) or (544/284) or (544/350)).CCLS.) and (quinazolinone or quinazolone or quinazolin) and (alkoxy or methoxy or ethoxy or propoxy or butoxy)	USPAT; US-PGPUB	2004/05/23 16:24
6	119	((514/234.2) or (514/234.5) or (514/249) or (514/252.17) or (514/264.1) or (514/266.2) or (514/266.21)).CCLS.) or ((544/116) or (544/117) or (544/279) or (544/284) or (544/350)).CCLS.) and (quinazolinone or quinazolone or quinazolin) and (alkoxy or methoxy or ethoxy or propoxy or butoxy) and (piperidino or piperazino)	USPAT; US-PGPUB	2004/05/23 16:25

10/ 040,319

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAPLUS
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEADLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	12	APR 26	PROMT: New display field available
NEWS	13	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	14	APR 26	LITALERT now available on STN
NEWS	15	APR 27	NLDB: New search and display fields available
NEWS	16	May 10	PROUSDDR now available on STN
NEWS	17	May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS	18	May 12	EXTEND option available in structure searching
NEWS	19	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	20	May 17	FRFULL now available on STN
NEWS EXPRESS			MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 15:16:54 ON 23 MAY 2004

10/ 040,319

=> file reg  
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 15:17:40 ON 23 MAY 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 MAY 2004 HIGHEST RN 684648-09-7  
DICTIONARY FILE UPDATES: 21 MAY 2004 HIGHEST RN 684648-09-7


TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>  
Uploading C:\STNEXP4\QUERIES\10040319a.str



chain nodes :

17 22 23

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 19 20

chain bonds :

1-17 5-11 22-23

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 11-12 11-16 12-13 13-14  
14-15 14-20 15-16 15-19

exact/norm bonds :

1-2 1-6 1-17 3-4 4-5 5-6 5-11 11-12 11-16 12-13 13-14 14-15 14-20 15-16  
15-19 22-23

normalized bonds :

2-3 2-7 3-10 7-8 8-9 9-10

isolated ring systems :

containing 1 :

G1:C,N

10/ 040,319

Hydrogen count :

6:= exact 1

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 19:Atom 20:Atom 22:CLASS  
23:CLASS 24:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful

FULL SEARCH INITIATED 15:18:06 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 10664 TO ITERATE

100.0% PROCESSED 10664 ITERATIONS  
SEARCH TIME: 00.00.01

229 ANSWERS

L2 229 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 15:18:13 ON 23 MAY 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

10/ 040,319

26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the  
American Chemical Society and is provided to assist you in searching  
databases on STN. Any dissemination, distribution, copying, or storing  
of this information, without the prior written consent of CAS, is  
strictly prohibited.

FILE COVERS 1907 - 23 May 2004 VOL 140 ISS 22  
FILE LAST UPDATED: 21 May 2004 (20040521/ED)

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> s l2  
L3

4 L2

=> d l3 1- ibib abs hitstr  
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):Y

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:267238 CAPLUS

DOCUMENT NUMBER: 140:281413

TITLE: Combinations of atorvastatin and  $\alpha$ 1-adrenergic  
receptor antagonists for the treatment of benign  
prostatic hyperplasia

INVENTOR(S): Pullen, Nicholas; Thurlow, Richard James

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 32 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026300	A1	20040401	WO 2003-IB3940	20030905
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: GB 2002-21579 A 20020917

AB Combinations of atorvastatin and  $\alpha$ 1 adrenergic antagonists, the use  
of such combinations in the treatment of benign prostatic hyperplasia  
(BPH), methods for treating BPH using such combinations, and medicaments  
containing such combinations are described. Preparation of an  $\alpha$ 1-adrenergic  
receptor antagonist, 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-  
dihydro[1,6]naphthyridin-6(5H)-yl)-4(3H)quinazolinone, is included.

IT 601517-31-1P 675819-75-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(atorvastatin- $\alpha$ 1-adrenergic receptor antagonist combination for  
treatment of benign prostatic hyperplasia)

RN 601517-31-1 CAPLUS

10/ 040,319

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-(4-morpholinylmethyl)-1,6-naphthyridin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 675819-75-7 CAPLUS

CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)-, mixt. with 5-cyclopropyl-2-[7,8-dihydro-2-(4-morpholinylmethyl)-1,6-naphthyridin-6(5H)-yl]-7-methoxy-4(1H)-quinazolinone (9CI) (CA INDEX NAME)

CM 1

CRN 601517-31-1

CMF C25 H29 N5 O3




CM 2

CRN 134523-00-5

CMF C33 H35 F N2 O5

Absolute stereochemistry.



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:737747 CAPLUS

DOCUMENT NUMBER: 139:261314

TITLE: Preparation of alkoxy quinazolinone compounds as  $\alpha$ 1L adrenoceptors antagonists useful in therapy  
 INVENTOR(S): Blagg, Julian; Fray, Michael Jonathan; Lewis, Mark Llewellyn; Mathias, John Paul; Stefaniak, Mark Henryk; Stobie, Alan

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 247 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076427	A1	20030918	WO 2003-IB998	20030305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004029859	A1	20040212	US 2003-387106	20030312
PRIORITY APPLN. INFO.:			GB 2002-6033	A 20020314
			US 2002-374894P	P 20020423

OTHER SOURCE(S): MARPAT 139:261314  
 GI



AB Quinazolinones (shown as I; variables defined below; e.g. 5-cyclopropyl-2-[5-[(cyclopropylamino)methyl]-3,4-dihydro-2(1H)-isoquinoliny]-7-methoxy-4(3H)-quinazolinone (II)) or pharmaceutically acceptable salts or solvates thereof are useful in the treatment of hypertension, myocardial infarction, male erectile dysfunction (MED), hyperlipidemia, cardiac arrhythmia, glaucoma and benign prostatic hyperplasia (BPH). For I: R1 = C1-4 alkyl; R2 = halo, C1-4 alkyl, C3-6 cycloalkyl, C3-6 cycloalkyloxy, -SO2(C1-4 alkyl), (un)substituted C1-4 alkyloxy, Het or -OHet; R3 = bicyclic II wherein X and Y = C and N, provided that at least one is C; Ring A together with X and Y = a 5- or 6-membered aromatic, ring containing 0-3 N atoms in the ring; n is 0-2; L = a direct link, C1-4 alkylene or C1-4 alkoxyalkylene; R4 = H, -NR5R6, C3-6 cycloalkyl, -OR7, Het1 or Het4; R5 and R6 = H, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-4 alkylene, -SO2(C1-4 alkyl) and (un)substituted C1-4 alkyl. R7 = H, C1-4 alkyl, C1-4 alkoxyalkyl, C3-6cycloalkyl, Het2 and C1-4alkyl-Het3; R8 is H or C1-4 alkyl; Het, Het1, Het2 and Het3 = an (un)substituted 4 to 7 membered saturated heterocyclic group which may be mono- or bi-cyclic and which contains  $\geq 1$  heteroatoms = N, O or S;

Het4 = an (un)substituted 5 or 6 membered unsatd. heterocyclic group containing  $\geq 1$  heteroatoms = N, O or S; R9 = H or C1-4 alkyl; R10 and R11 = H and C1-4 alkyl. They also find utility in the treatment of female sexual arousal dysfunction (FSAD).  $\alpha 1$ L adrenoceptors antagonist activity of 10 examples of I are tabulated. Three hundred seven example preps. and/or characterization data of intermediates and 133 of I are included. For example, II was prepared from N-[(1,2,3,4-tetrahydro-5-isoquinolinyl)methyl]cyclopropanamine dihydrochloride (preparation given), 2-chloro-5-cyclopropyl-7-methoxy-4(3H)-quinazolinone (preparation given) and diisopropylethylamine in butanol.

IT 601517-21-9P, 5-Cyclopropyl-2-[5-[(cyclopropylamino)methyl]-3,4-dihydro-2(1H)-isoquinolinyl]-7-methoxy-4(3H)-quinazolinone  
 601517-22-0P, 5-Cyclopropyl-2-[5-[[[(cyclopropyl)(methyl)amino]methyl]-3,4-dihydro-2(1H)-isoquinolinyl]-7-methoxy-4(3H)-quinazolinone  
 601517-23-1P, 5-Cyclopropyl-2-[5-[(3-azabicyclo[3.1.0]hex-3-yl)methyl]-3,4-dihydro-2(1H)-isoquinolinyl]-7-methoxy-4(3H)-quinazolinone  
 601517-24-2P, 5-Cyclopropyl-2-[5-[(4-methylpiperazin-1-yl)methyl]-3,4-dihydro-2(1H)-isoquinolinyl]-7-methoxy-4(3H)-quinazolinone  
 601517-25-3P, 5-Cyclopropyl-2-[5-[(1-methylpiperidin-4-yl)oxy]-3,4-dihydro-2(1H)-isoquinolinyl]-7-methoxy-4(3H)-quinazolinone  
 601517-26-4P, 5-Cyclopropyl-2-[2-(methylamino)-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-7-methoxy-4(3H)-quinazolinone  
 601517-27-5P, 5-Cyclopropyl-2-[2-[(dimethylamino)methyl]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-7-methoxy-4(3H)-quinazolinone  
 601517-28-6P, 5-Cyclopropyl-2-[2-[(pyrrolidin-1-yl)methyl]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-7-methoxy-4(3H)-quinazolinone  
 601517-29-7P, 5-Cyclopropyl-2-[2-[(3-azabicyclo[3.1.0]hex-3-yl)methyl]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-7-methoxy-4(3H)-quinazolinone 601517-30-0P, 5-Cyclopropyl-2-[2-[(4-methoxypiperidin-1-yl)methyl]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-7-methoxy-4(3H)-quinazolinone 601517-31-1P, 5-Cyclopropyl-2-[2-[(morpholin-4-yl)methyl]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-7-methoxy-4(3H)-quinazolinone 601517-32-2P, 5-Cyclopropyl-7-methoxy-2-[2-[(1S,4S)-2-aza-5-oxabicyclo[2.2.1]hept-2-yl)methyl]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone 601517-33-3P, 5-Cyclopropyl-7-methoxy-2-[2-(morpholin-4-yl)-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone 601517-34-4P, 5-Cyclopropyl-7-methoxy-2-[2-(4-methylpiperazin-1-yl)-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone 601517-35-5P, 5-Cyclopropyl-7-methoxy-2-[1-amino-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone 601517-36-6P, 5-Cyclopropyl-7-methoxy-2-[1-[(dimethylamino)methyl]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone 601517-37-7P, 5-Cyclopropyl-7-methoxy-2-[1-[(isopropyl)(methyl)amino]methyl]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone 601517-38-8P, 5-Cyclopropyl-7-methoxy-2-[1-[(7-azabicyclo[2.2.1]hept-7-yl)methyl]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone 601517-39-9P, 5-Cyclopropyl-7-methoxy-2-[1-[(4-methoxypiperidin-1-yl)methyl]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone 601517-40-2P, 5-Cyclopropyl-7-methoxy-2-[1-[(morpholin-4-yl)methyl]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone 601517-41-3P, 5-Cyclopropyl-7-methoxy-2-[1-[(1S,4S)-2-aza-5-oxabicyclo[2.2.1]hept-2-yl)methyl]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone 601517-42-4P, 5-Cyclopropyl-7-methoxy-2-[4-[(pyrrolidin-1-yl)methyl]-5,6-dihydropyrido[3,4-d]pyrimidin-7(8H)-yl]-4(3H)-quinazolinone 601517-43-5P, 5-Cyclopropyl-7-methoxy-2-[4-[(piperidin-1-yl)methyl]-5,6-dihydropyrido[3,4-d]pyrimidin-7(8H)-yl]-4(3H)-quinazolinone 601517-44-6P, 5-Cyclopropyl-7-methoxy-2-[4-[(4-methoxypiperidin-1-yl)methyl]-5,6-dihydropyrido[3,4-d]pyrimidin-7(8H)-yl]-4(3H)-quinazolinone 601517-46-8P, 5-Cyclopropyl-7-methoxy-2-[2-[(1-piperidinyl)methyl]-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl]-4(3H)-quinazolinone 601517-50-4P, 5-Cyclopropyl-7-methoxy-2-[5-(1-methyl-4-piperidinyl)-3,4-dihydro-[2,6]naphthyridin-2(1H)-yl]-4(3H)-quinazolinone



**601517-53-7P**, 5-Cyclobutyl-7-methoxy-2-[2-[(4-morpholinyl)methyl]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone  
**601517-54-8P**, 5-Cyclohexyl-7-methoxy-2-[2-[(4-morpholinyl)methyl]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone  
**601517-55-9P**, 5-Cyclopropyl-7-methoxy-2-[5-[(morpholin-4-yl)methyl]-3,4-dihydroisoquinolin-2(1H)-yl]-4(3H)-quinazolinone dihydrochloride **601517-56-0P**, 5-Cyclopropyl-7-methoxy-2-[5-[(3-methoxyazetid-1-yl)methyl]-3,4-dihydroisoquinolin-2(1H)-yl]-4(3H)-quinazolinone dihydrochloride **601517-57-1P**, 5-Cyclopropyl-7-methoxy-2-[7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone dihydrochloride **601517-58-2P**, 5-Cyclopropyl-7-methoxy-2-[1-[(pyrrolidin-1-yl)methyl]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone dihydrochloride **601517-59-3P**, 5-Cyclopropyl-7-methoxy-2-[1-[(piperidin-1-yl)methyl]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone dihydrochloride **601517-60-6P**, 5-Cyclopropyl-2-[2-[(dimethylamino)methyl]-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl]-7-methoxy-4(3H)-quinazolinone dihydrochloride **601517-61-7P**, 5-Cyclopropyl-7-methoxy-2-[2-[(pyrrolidin-1-yl)methyl]-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl]-4(3H)-quinazolinone dihydrochloride **601517-65-1P**, 5-Cyclopropyl-7-methoxy-2-[2-[(2-methoxyethyl)(methyl)amino]methyl]-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl]-4(3H)-quinazolinone hydrochloride **601517-66-2P**, 5-Cyclopropyl-7-methoxy-2-[2-[[2-(4-morpholinyl)ethoxy]methyl]-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl]-4(3H)-quinazolinone hydrochloride **601517-70-8P**, 5-Isopropyl-7-methoxy-2-[7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601517-71-9P**, 5-Isopropyl-7-methoxy-2-[5-[(morpholin-4-yl)methyl]-3,4-dihydroisoquinolin-2(1H)-yl]-4(3H)-quinazolinone **601517-72-0P**, 5-Isopropyl-7-methoxy-2-[2-[(pyridin-2-yl)methyl]amino]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601517-73-1P**, 5-Cyclobutoxy-7-methoxy-2-[5-[(methylsulfonyl)amino]-3,4-dihydroisoquinolin-2(1H)-yl]-4(3H)-quinazolinone **601517-75-3P**, 5-Isopropoxy-7-methoxy-2-[7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601517-76-4P**, 5-Isopropoxy-7-methoxy-2-[2-[(2-methoxyethyl)amino]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601517-77-5P**, 5-Cyclobutoxy-7-methoxy-2-[5-[(diethylamino)methyl]-3,4-dihydroisoquinolin-2(1H)-yl]-4(3H)-quinazolinone **601517-79-7P**, 5-[(Tetrahydrofuran-3-yl)oxy]-7-methoxy-2-[7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601517-80-0P**, 5-[(Tetrahydrofuran-3-yl)oxy]-7-methoxy-2-[2-[(2-methoxyethyl)amino]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601517-81-1P**, 5-[(Tetrahydrofuran-3-yl)oxy]-7-methoxy-2-[2-[(pyridin-2-yl)methyl]amino]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601517-82-2P**, 5-(2-Methoxyethoxy)-7-methoxy-2-[7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601517-83-3P**, 5-(2-Methoxyethoxy)-7-methoxy-2-[1-[(pyridin-2-yl)methyl]amino]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601517-84-4P**, 5-(2-Methoxyethoxy)-7-methoxy-2-[2-[(2-methoxyethyl)amino]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601517-85-5P**, 5-(2-Methoxyethoxy)-7-methoxy-2-[2-[[pyridin-2-yl)methyl]amino]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601517-86-6P**, 5-(Cyclopropylmethoxy)-7-methoxy-2-[7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601517-87-7P**, 5-(Cyclopropylmethoxy)-7-methoxy-2-[1-[(pyridin-2-yl)methyl]amino]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601517-88-8P**, 5-(Cyclopropylmethoxy)-7-methoxy-2-[2-[[pyridin-2-yl)methyl]amino]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601517-89-9P**, 5-Isopropoxy-7-methoxy-2-[2-[[pyridin-2-yl)methyl]amino]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601517-90-2P**, 5-Cyclopropyl-7-methoxy-2-[5-[(S)-1-methylpyrrolidin-3-yl]oxy]-3,4-dihydroisoquinolin-2(1H)-yl]-4(3H)-quinazolinone **601517-91-3P**, 5-Cyclopropyl-7-methoxy-2-[5-[(R)-1-methylpyrrolidin-3-yl]oxy]-3,4-dihydroisoquinolin-2(1H)-yl]-4(3H)-

quinazolinone **601517-92-4P**, 5-Cyclopropyl-7-methoxy-2-[5-[(S)-1-methylpyrrolidin-2-yl)methoxy]-3,4-dihydroisoquinolin-2(1H)-yl]-4(3H)-  
 quinazolinone **601517-93-5P**, 5-Cyclopropyl-7-methoxy-2-[5-[(R)-1-methylpyrrolidin-2-yl)methoxy]-3,4-dihydroisoquinolin-2(1H)-yl]-4(3H)-  
 quinazolinone **601517-94-6P**, 5-Cyclopropyl-7-methoxy-2-[2-methyl-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone  
**601517-95-7P**, 5-Cyclopropyl-7-methoxy-2-[2-(4-methylpiperidin-4-yl)-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone  
**601517-96-8P**, 5-Cyclopropyl-7-methoxy-2-[2-[(2-hydroxyethyl)amino]methyl]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-  
 quinazolinone **601517-97-9P**, 5-Cyclopropyl-7-methoxy-2-[2-[(2-methoxyethyl)(methyl)amino]methyl]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601517-98-0P**, 5-Cyclopropyl-7-methoxy-2-[1-[(3-methoxyazetidin-1-yl)methyl]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601517-99-1P**, 5-Cyclopropyl-7-methoxy-2-[1-[(S)-3-methoxypyrrolidin-1-yl)methyl]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601518-00-7P**, 5-Cyclopropyl-7-methoxy-2-[1-[(1R,4R)-2-aza-5-oxabicyclo[2.2.1]hept-2-yl)methyl]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601518-01-8P**, 5-Cyclopropyl-7-methoxy-2-[2-[[[(S)-1-(methoxymethyl)ethyl](methyl)amino]methyl]-7,8-dihydro-4,3-d]pyrimidin-6(5H)-yl]-4(3H)-quinazolinone **601518-02-9P**, 5-Cyclopropyl-7-methoxy-2-[2-[(4-methoxypiperidin-1-yl)methyl]-7,8-dihydro-4,3-d]pyrimidin-6(5H)-yl]-4(3H)-quinazolinone **601518-05-2P**, 5-Cyclopropyl-7-methoxy-2-[2-[(1R,4R)-2-aza-5-oxabicyclo[2.2.1]hept-2-yl)methyl]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601518-06-3P**, 5-Isopropyl-7-methoxy-2-[2-[(2-methoxyethyl)amino]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone **601518-07-4P**, 5-Isopropyl-7-methoxy-2-[5-[(morpholin-4-yl)methyl]-3,4-dihydro-1H-[2,6]naphthyridin-2-yl]-3H-quinazolin-4-one dihydrochloride **601518-08-5P**, 5-Isopropyl-7-methoxy-2-[1-[(2-methoxyethyl)(methyl)amino]methyl]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone hydrochloride **601518-09-6P**, 5-Isopropyl-7-methoxy-2-[2-[(pyrrolidin-1-yl)methyl]-7,8-dihydro-4,3-d]pyrimidin-6(5H)-yl]-4(3H)-quinazolinone hydrochloride **601518-10-9P**, 5-Isopropyl-7-methoxy-2-[1-amino-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone hydrochloride **601518-11-0P**, 5-Isopropyl-7-methoxy-2-[4-amino-2-[(2-methoxyethyl)amino]-7,8-dihydro-4,3-d]pyrimidin-6(5H)-yl]-4(3H)-quinazolinone hydrochloride **601518-12-1P**, 5-Isopropyl-7-methoxy-2-[2-(methylamino)-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone hydrochloride **601518-13-2P**, 5-Isopropyl-7-methoxy-2-[4-[(ethyl)(methyl)amino]-5,6-dihydro-4,3-d]pyrimidin-7(8H)-yl]-4(3H)-quinazolinone hydrochloride **601518-14-3P**, 5-Isopropyl-7-methoxy-2-[5-[(3-methoxyazetidin-1-yl)methyl]-3,4-dihydroisoquinolin-2(1H)-yl]-4(3H)-quinazolinone hydrochloride **601518-15-4P**, 5-Isopropyl-7-methoxy-2-[1-[(pyridin-2-yl)methyl]amino]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone hydrochloride **601518-16-5P**, 5-Isopropyl-7-methoxy-2-[5-[(2-methoxyethyl)amino]methyl]-3,4-dihydroisoquinolin-2(1H)-yl]-4(3H)-quinazolinone hydrochloride **601518-17-6P**, 5-Isopropyl-7-methoxy-2-[1-[(2-(dimethylamino)ethyl)amino]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone hydrochloride **601518-18-7P**, 5-Isopropyl-7-methoxy-2-[5-[(dimethylamino)methyl]-3,4-dihydroisoquinolin-2(1H)-yl]-4(3H)-quinazolinone hydrochloride **601518-21-2P 601518-22-3P 601518-23-4P**, 5-Isopropyl-7-methoxy-2-[2-[(morpholin-4-yl)methyl]-7,8-dihydro-4,3-d]pyrimidin-6(5H)-yl]-4(3H)-quinazolinone hydrochloride **601518-24-5P**, 5-Isopropyl-7-methoxy-2-[1-[(dimethylamino)methyl]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone hydrochloride **601518-25-6P**, 5-Isopropyl-7-methoxy-2-[2-[(2-(dimethylamino)ethyl)amino]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4(3H)-quinazolinone hydrochloride **601518-26-7P**, 5-Isopropyl-7-methoxy-2-[5-[(2-methylimidazol-1-yl)methyl]-3,4-dihydroisoquinolin-2(1H)-yl]-


4 (3H)-quinazolinone hydrochloride **601518-27-8P**,  
 5-(2H-Tetrahydropyran-4-yl)-7-methoxy-2-[2-[(2-methoxyethyl)(methyl)amino]methyl]-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl]-4 (3H)-quinazolinone hydrochloride **601518-28-9P**,  
 5-(2H-Tetrahydropyran-4-yl)-7-methoxy-2-[2-[(pyrrolidin-1-yl)methyl]-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl]-4 (3H)-quinazolinone hydrochloride **601518-29-0P**, 5-(2H-Tetrahydropyran-4-yl)-7-methoxy-2-[2-[(dimethylamino)methyl]-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl]-4 (3H)-quinazolinone hydrochloride **601518-30-3P**, 5-(2H-Tetrahydropyran-4-yl)-7-methoxy-2-[1-[(pyrrolidin-1-yl)methyl]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4 (3H)-quinazolinone hydrochloride **601518-32-5P**, 5-(2H-Tetrahydropyran-4-yl)-7-methoxy-2-[1-[(morpholin-4-yl)methyl]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4 (3H)-quinazolinone hydrochloride **601518-33-6P**, 5-(2H-Tetrahydropyran-4-yl)-7-methoxy-2-[1-[(dimethylamino)methyl]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4 (3H)-quinazolinone hydrochloride **601518-34-7P**,  
 5-(2H-Tetrahydropyran-4-yl)-7-methoxy-2-[5-[(morpholin-4-yl)methyl]-3,4-dihydroisoquinolin-2(1H)-yl]-4 (3H)-quinazolinone hydrochloride **601518-35-8P**, 5-(2H-Tetrahydropyran-4-yl)-7-methoxy-2-[5-[(3-methoxyazetid-1-yl)methyl]-3,4-dihydroisoquinolin-2(1H)-yl]-4 (3H)-quinazolinone hydrochloride **601518-36-9P**, 5-(Tetrahydrofuran-2-yl)-7-methoxy-2-[2-[[2-(pyrrolidin-1-yl)ethyl]amino]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4 (3H)-quinazolinone hydrochloride **601518-37-0P**, 5-(Tetrahydrofuran-2-yl)-7-methoxy-2-[2-[(2-methoxyethyl)amino]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4 (3H)-quinazolinone hydrochloride **601518-38-1P**, 5-(Tetrahydrofuran-2-yl)-7-methoxy-2-[2-[[2-(dimethylamino)ethyl]amino]-7,8-dihydro-[1,6]naphthyridin-6(5H)-yl]-4 (3H)-quinazolinone hydrochloride **601518-39-2P**, 5-(Tetrahydrofuran-2-yl)-7-methoxy-2-[1-amino-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4 (3H)-quinazolinone hydrochloride **601518-40-5P**, 5-Chloro-7-methoxy-2-[2-[(pyrrolidin-1-yl)methyl]-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl]-4 (3H)-quinazolinone hydrochloride **601518-41-6P**, 5-Chloro-7-methoxy-2-[1-[(1S,4S)-2-aza-5-oxabicyclo[2.2.1]hept-2-yl)methyl]-7,8-dihydro-[2,6]naphthyridin-6(5H)-yl]-4 (3H)-quinazolinone hydrochloride **601518-42-7P**,  
 5-Cyclopropyl-7-methoxy-2-[2-[[ethyl(2-methoxyethyl)amino]methyl]-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl]-4 (3H)-quinazolinone hydrochloride **601518-43-8P**, 2-(2-Aminomethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-5-isopropyl-7-methoxy-3H-quinazolin-4-one dihydrochloride **601518-44-9P**, 2-(7,8-Dihydro-5H-[1,6]naphthyridin-6-yl)-7-methoxy-5-(1-methylpiperidin-2-yl)-3H-quinazolin-4-one trihydrochloride **601518-45-0P**, 2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-7-methoxy-5-(1-methylpiperidin-2-yl)-3H-quinazolin-4-one dihydrochloride **601518-46-1P**, 7-Methoxy-2-[6-[(2-methoxyethyl)amino]-3,4-dihydro-1H-isoquinolin-2-yl]-5-(1-methylpiperidin-2-yl)-3H-quinazolin-4-one trihydrochloride **601518-47-2P**, 5-(Butan-1-ylsulfonyl)-7-methoxy-2-[5-[(2-methoxyethyl)amino]-3,4-dihydro-1H-[2,6]naphthyridin-2-yl]-3H-quinazolin-4-one **601518-48-3P**, 5-(Butan-1-ylsulfonyl)-7-methoxy-2-[5-[[pyridin-2-yl)methyl]amino]-3,4-dihydro-1H-[2,6]naphthyridin-2-yl]-3H-quinazolin-4-one **601518-49-4P**, 5-Isopropyl-7-methoxy-2-[1-[2-(pyrrolidin-1-yl)ethyl]-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]-3H-quinazolin-4-one **601518-51-8P**, 5-Chloro-7-methoxy-2-[5-[(pyrrolidin-1-yl)methyl]-3,4-dihydro-1H-[2,6]naphthyridin-2-yl]-3H-quinazolin-4-one dihydrochloride **601518-52-9P**,  
 5-Isopropyl-7-methoxy-2-[2-(4-methylpiperazin-1-yl)-7,8-dihydro-5H-[1,6]naphthyridin-6-yl]-3H-quinazolin-4-one trihydrochloride **601518-53-0P**, 5-Isopropyl-7-methoxy-2-[5-[(methylamino)methyl]-3,4-dihydro-1H-[2,6]naphthyridin-2-yl]-3H-quinazolin-4-one dihydrochloride  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of alkoxy quinazolinone compds. as  $\alpha 1L$  adrenoceptors antagonists useful in therapy)

10/ 040,319


RN 601517-21-9 CAPLUS

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[5-[(cyclopropylamino)methyl]-3,4-dihydro-2(1H)-isoquinolinyl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 601517-22-0 CAPLUS

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[5-[(cyclopropylmethylamino)methyl]-3,4-dihydro-2(1H)-isoquinolinyl]-7-methoxy- (9CI) (CA INDEX NAME)



RN 601517-23-1 CAPLUS

CN 4(1H)-Quinazolinone, 2-[5-(3-azabicyclo[3.1.0]hex-3-ylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl]-5-cyclopropyl-7-methoxy- (9CI) (CA INDEX NAME)




RN 601517-24-2 CAPLUS

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-[(4-methyl-1-


10/ 040,319

piperazinyl)methyl]-2(1H)-isoquinolinyl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 601517-25-3 CAPLUS

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-[(1-methyl-4-piperidinyl)oxy]-2(1H)-isoquinolinyl]-7-methoxy- (9CI) (CA INDEX NAME)



RN 601517-26-4 CAPLUS

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-(methylamino)-1,6-naphthyridin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 601517-27-5 CAPLUS

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[2-[(dimethylamino)methyl]-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)


10/ 040,319

dihydro-1,6-naphthyridin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 601517-28-6 CAPLUS

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-(1-pyrrolidinylmethyl)-1,6-naphthyridin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 601517-29-7 CAPLUS

CN 4(1H)-Quinazolinone, 2-[2-(3-azabicyclo[3.1.0]hex-3-ylmethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]-5-cyclopropyl-7-methoxy- (9CI) (CA INDEX NAME)



RN 601517-30-0 CAPLUS


CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-[(4-methoxy-1-piperidinyl)methyl]-1,6-naphthyridin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)



RN 601517-31-1 CAPLUS

10/ 040,319


CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-(4-morpholinylmethyl)-1,6-naphthyridin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)



RN 601517-32-2 CAPLUS


CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl]-1,6-naphthyridin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 601517-33-3 CAPLUS


CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-(4-morpholinyl)-1,6-naphthyridin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 601517-34-4 CAPLUS

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-(4-methyl-1-piperazinyl)-1,6-naphthyridin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)


10/ 040,319



RN 601517-35-5 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(5-amino-3,4-dihydro-2,6-naphthyridin-2(1H)-yl)-5-cyclopropyl-7-methoxy- (9CI) (CA INDEX NAME)




RN 601517-36-6 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[5-[(dimethylamino)methyl]-3,4-dihydro-2,6-naphthyridin-2(1H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 601517-37-7 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-[[methyl(1-methylethyl)amino]methyl]-2,6-naphthyridin-2(1H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)






RN 601517-38-8 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[5-(7-azabicyclo[2.2.1]hept-7-ylmethyl)-3,4-dihydro-2,6-naphthyridin-2(1H)-yl]-5-cyclopropyl-7-methoxy- (9CI) (CA INDEX NAME)




RN 601517-39-9 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-[(4-methoxy-1-piperidinyl)methyl]-2,6-naphthyridin-2(1H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)



RN 601517-40-2 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-(4-morpholinylmethyl)-2,6-naphthyridin-2(1H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)


10/ 040,319



RN 601517-41-3 CAPLUS


CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl]-2,6-naphthyridin-2(1H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 601517-42-4 CAPLUS

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[5,8-dihydro-4-(1-pyrrolidinylmethyl)pyrido[3,4-d]pyrimidin-7(6H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)




10/ 040,319


RN 601517-43-5 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[5,8-dihydro-4-(1-piperidinylmethyl)pyrido[3,4-d]pyrimidin-7(6H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)



RN 601517-44-6 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[5,8-dihydro-4-[(4-methoxy-1-piperidinyl)methyl]pyrido[3,4-d]pyrimidin-7(6H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 601517-46-8 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-(1-piperidinylmethyl)pyrido[4,3-d]pyrimidin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 601517-50-4 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-(1-methyl-4-piperidinyl)-2,6-naphthyridin-2(1H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)


10/ 040,319



RN 601517-53-7 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclobutyl-2-[7,8-dihydro-2-(4-morpholinylmethyl)-1,6-naphthyridin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 601517-54-8 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclohexyl-2-[7,8-dihydro-2-(4-morpholinylmethyl)-1,6-naphthyridin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 601517-55-9 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-(4-morpholinylmethyl)-2(1H)-isoquinolinyl]-7-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)

10/ 040,319



● 2 HCl


RN 601517-56-0 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-[(3-methoxy-1-azetidiny)methyl]-2(1H)-isoquinolinyl]-7-methoxy-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl


RN 601517-57-1 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-7-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)

10/ 040,319



● 2 HCl


RN 601517-58-2 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-(1-pyrrolidinylmethyl)-  
2,6-naphthyridin-2(1H)-yl]-7-methoxy-, dihydrochloride (9CI) (CA INDEX  
NAME)



● 2 HCl


RN 601517-59-3 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-(1-piperidinylmethyl)-  
2,6-naphthyridin-2(1H)-yl]-7-methoxy-, dihydrochloride (9CI) (CA INDEX  
NAME)

10/ 040,319




● 2 HCl

RN 601517-60-6 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[2-[(dimethylamino)methyl]-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl]-7-methoxy-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl

RN 601517-61-7 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-(1-pyrrolidinylmethyl)pyrido[4,3-d]pyrimidin-6(5H)-yl]-7-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

10/ 040,319


RN 601517-65-1 CAPLUS

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-[[2-methoxyethyl)methylamino)methyl]pyrido[4,3-d]pyrimidin-6(5H)-yl]-7-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




RN 601517-66-2 CAPLUS

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-[[2-(4-morpholinyl)ethoxy)methyl]pyrido[4,3-d]pyrimidin-6(5H)-yl]-7-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



RN 601517-70-8 CAPLUS

CN 4(1H)-Quinazolinone, 2-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-7-methoxy-5-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 601517-71-9 CAPLUS

CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(4-morpholinylmethyl)-2(1H)-




10/ 040,319

isoquinolinyl]-7-methoxy-5-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 601517-72-0 CAPLUS

CN 4(1H)-Quinazolinone, 2-[7,8-dihydro-2-[(2-pyridinylmethyl)amino]-1,6-naphthyridin-6(5H)-yl]-7-methoxy-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 601517-73-1 CAPLUS


CN Methanesulfonamide, N-[2-[5-(cyclobutyloxy)-1,4-dihydro-7-methoxy-4-oxo-2-quinazolinyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]- (9CI) (CA INDEX NAME)




RN 601517-75-3 CAPLUS

CN 4(1H)-Quinazolinone, 2-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-7-methoxy-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)


10/ 040,319



RN 601517-76-4 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[7,8-dihydro-2-[(2-methoxyethyl)amino]-1,6-naphthyridin-6(5H)-yl]-7-methoxy-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 601517-77-5 CAPLUS  
CN 4(1H)-Quinazolinone, 5-(cyclobutyloxy)-2-[5-[(diethylamino)methyl]-3,4-dihydro-2(1H)-isoquinolinyl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 601517-79-7 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-7-methoxy-5-[(tetrahydro-3-furanyl)oxy]- (9CI) (CA INDEX NAME)


10/ 040,319



RN 601517-80-0 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[7,8-dihydro-2-[(2-methoxyethyl)amino]-1,6-naphthyridin-6(5H)-yl]-7-methoxy-5-[(tetrahydro-3-furanyl)oxy]- (9CI) (CA INDEX NAME)




RN 601517-81-1 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[7,8-dihydro-2-[(2-pyridinylmethyl)amino]-1,6-naphthyridin-6(5H)-yl]-7-methoxy-5-[(tetrahydro-3-furanyl)oxy]- (9CI) (CA INDEX NAME)




RN 601517-82-2 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-7-methoxy-5-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)


10/ 040,319




RN 601517-83-3 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-[(2-pyridinylmethyl)amino]-2,6-naphthyridin-2(1H)-yl]-7-methoxy-5-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



RN 601517-84-4 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[7,8-dihydro-2-[(2-methoxyethyl)amino]-1,6-naphthyridin-6(5H)-yl]-7-methoxy-5-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)



RN 601517-85-5 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[7,8-dihydro-2-[(2-pyridinylmethyl)amino]-1,6-naphthyridin-6(5H)-yl]-7-methoxy-5-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)





3


1



**Abstract**


CN 4(1H)-Quinazolinone, 5-(cyclopropylmethoxy)-2-[7,8-dihydro-2-[(2-pyridinylmethyl)amino]-1,6-naphthyridin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)

10/ 040,319



RN 601517-89-9 CAPLUS


CN 4(1H)-Quinazolinone, 2-[7,8-dihydro-2-[(2-pyridinylmethyl)amino]-1,6-naphthyridin-6(5H)-yl]-7-methoxy-5-(1-methylethoxy)-(9CI) (CA INDEX NAME)



RN 601517-90-2 CAPLUS

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-[[ (3S)-1-methyl-3-pyrrolidinyl]oxy]-2(1H)-isoquinolinyl]-7-methoxy-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 601517-91-3 CAPLUS

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-[[ (3R)-1-methyl-3-pyrrolidinyl]oxy]-2(1H)-isoquinolinyl]-7-methoxy-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/ 040,319



RN 601517-92-4 CAPLUS

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-[[2-(1-methyl-2-pyrrolidinyl)methoxy]-2(1H)-isoquinolinyl]-7-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 601517-93-5 CAPLUS

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-[[2-(1-methyl-2-pyrrolidinyl)methoxy]-2(1H)-isoquinolinyl]-7-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/ 040,319




RN 601517-94-6 CAPLUS

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-(7,8-dihydro-2-methyl-1,6-naphthyridin-6(5H)-yl)-7-methoxy- (9CI) (CA INDEX NAME)



RN 601517-95-7 CAPLUS

CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-(1-methyl-4-piperidinyl)-1,6-naphthyridin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 601517-96-8 CAPLUS


CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-[(2-hydroxyethyl)amino]methyl]-1,6-naphthyridin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)




10/ 040,319



RN 601517-97-9 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-[[2-methoxyethyl)methylamino)methyl]-1,6-naphthyridin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 601517-98-0 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-[(3-methoxy-1-azetidyl)methyl]-2,6-naphthyridin-2(1H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)



RN 601517-99-1 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-[(3S)-3-methoxy-1-pyrrolidinyl)methyl]-2,6-naphthyridin-2(1H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/ 040,319



RN 601518-00-7 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[3,4-dihydro-5-[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl]-2,6-naphthyridin-2(1H)-yl]-7-methoxy-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 601518-01-8 CAPLUS  
CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-[[[(1S)-2-methoxy-1-methylethyl]methylamino]methyl]pyrido[4,3-d]pyrimidin-6(5H)-yl]-7-methoxy-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/ 040,319




RN 601518-02-9 CAPLUS  
 CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-[(4-methoxy-1-piperidinyl)methyl]pyrido[4,3-d]pyrimidin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 601518-05-2 CAPLUS  
 CN 4(1H)-Quinazolinone, 5-cyclopropyl-2-[7,8-dihydro-2-[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl]-1,6-naphthyridin-6(5H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 601518-06-3 CAPLUS  
 CN 4(1H)-Quinazolinone, 2-[7,8-dihydro-2-[(2-methoxyethyl)amino]-1,6-naphthyridin-6(5H)-yl]-7-methoxy-5-(1-methylethyl)- (9CI) (CA INDEX NAME)

10/ 040,319




RN 601518-07-4 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(4-morpholinylmethyl)-2,6-naphthyridin-2(1H)-yl]-7-methoxy-5-(1-methylethyl)-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl


RN 601518-08-5 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-[[ (2-methoxyethyl)methylamino]methyl]-2,6-naphthyridin-2(1H)-yl]-7-methoxy-5-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 601518-09-6 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[7,8-dihydro-2-(1-pyrrolidinylmethyl)pyrido[4,3-d]pyrimidin-6(5H)-yl]-7-methoxy-5-(1-methylethyl)-, hydrochloride (9CI)  
(CA INDEX NAME)

10/ 040,319




● x HCl

RN 601518-10-9 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(5-amino-3,4-dihydro-2,6-naphthyridin-2(1H)-yl)-7-methoxy-5-(1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 601518-11-0 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[4-amino-7,8-dihydro-2-[(2-methoxyethyl)amino]pyrido[4,3-d]pyrimidin-6(5H)-yl]-7-methoxy-5-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 601518-12-1 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[7,8-dihydro-2-(methylamino)-1,6-naphthyridin-6(5H)-yl]-7-methoxy-5-(1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)

10/ 040,319




● x HCl

RN 601518-13-2 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[4-(ethylmethylanino)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-7-methoxy-5-(1-methylethyl)-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl

RN 601518-14-3 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-[(3-methoxy-1-azetidiny)methyl]-2(1H)-isoquinolinyl]-7-methoxy-5-(1-methylethyl)-, dihydrochloride (9CI)  
(CA INDEX NAME)




● 2 HCl

RN 601518-15-4 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-[(2-pyridinyl)methyl]amino]-2,6-naphthyridin-2(1H)-yl]-7-methoxy-5-(1-methylethyl)-, trihydrochloride


10/ 040,319

(9CI) (CA INDEX NAME)



●3 HCl


RN 601518-16-5 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-[[2-(2-methoxyethyl)amino]methyl]-2(1H)-isoquinolinyl]-7-methoxy-5-(1-methylethyl)-, dihydrochloride (9CI)  
(CA INDEX NAME)



●2 HCl


RN 601518-17-6 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[5-[[2-(dimethylamino)ethyl]amino]-3,4-dihydro-2,6-naphthyridin-2(1H)-yl]-7-methoxy-5-(1-methylethyl)-, trihydrochloride  
(9CI) (CA INDEX NAME)

10/ 040,319




● 3 HCl

RN 601518-18-7 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[5-[(dimethylamino)methyl]-3,4-dihydro-2(1H)-isoquinolinyl]-7-methoxy-5-(1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 601518-21-2 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-[(4-methoxy-1-piperidiny)methyl]-2,6-naphthyridin-2(1H)-yl]-7-methoxy-5-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl




10/ 040,319

RN 601518-22-3 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-[(3-methoxy-1-azetidyl)methyl]-2,6-naphthyridin-2(1H)-yl]-7-methoxy-5-(1-methylethyl)-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl


RN 601518-23-4 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[7,8-dihydro-2-(4-morpholinylmethyl)pyrido[4,3-d]pyrimidin-6(5H)-yl]-7-methoxy-5-(1-methylethyl)-, dihydrochloride (9CI)  
(CA INDEX NAME)



● 2 HCl


RN 601518-24-5 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[5-[(dimethylamino)methyl]-3,4-dihydro-2,6-naphthyridin-2(1H)-yl]-7-methoxy-5-(1-methylethyl)-, dihydrochloride (9CI)  
(CA INDEX NAME)

10/ 040,319




● 2 HCl

RN 601518-25-6 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[2-[[2-(dimethylamino)ethyl]amino]-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]-7-methoxy-5-(1-methylethyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 601518-26-7 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-[(2-methyl-1H-imidazol-1-yl)methyl]-2(1H)-isoquinolinyl]-7-methoxy-5-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 601518-27-8 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[7,8-dihydro-2-[[[(2-methoxyethyl)methylamino]methyl]pyrido[4,3-d]pyrimidin-6(5H)-yl]-7-methoxy-5-(tetrahydro-2H-pyran-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)


10/ 040,319

monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 601518-28-9 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[7,8-dihydro-2-(1-pyrrolidinylmethyl)pyrido[4,3-d]pyrimidin-6(5H)-yl]-7-methoxy-5-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 601518-29-0 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[2-[(dimethylamino)methyl]-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl]-7-methoxy-5-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (5:8) (9CI) (CA INDEX NAME)

10/ 040,319



● 8/5 HCl


RN 601518-30-3 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(1-pyrrolidinylmethyl)-2,6-naphthyridin-2(1H)-yl]-7-methoxy-5-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 601518-32-5 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(4-morpholinylmethyl)-2,6-naphthyridin-2(1H)-yl]-7-methoxy-5-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)

10/ 040,319



●x HCl


RN 601518-33-6 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[5-[(dimethylamino)methyl]-3,4-dihydro-2,6-naphthyridin-2(1H)-yl]-7-methoxy-5-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 601518-34-7 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(4-morpholinylmethyl)-2(1H)-isoquinolinyl]-7-methoxy-5-(tetrahydro-2H-pyran-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)

10/ 040,319



● 2 HCl


RN 601518-35-8 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-[(3-methoxy-1-azetidinyl)methyl]-2(1H)-isoquinolinyl]-7-methoxy-5-(tetrahydro-2H-pyran-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 601518-36-9 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[7,8-dihydro-2-[[2-(1-pyrrolidinyl)ethyl]amino]-1,6-naphthyridin-6(5H)-yl]-7-methoxy-5-(tetrahydro-2-furanyl)-, trihydrochloride (9CI) (CA INDEX NAME)

10/ 040,319




●3 HCl

RN 601518-37-0 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[7,8-dihydro-2-[(2-methoxyethyl)amino]-1,6-naphthyridin-6(5H)-yl]-7-methoxy-5-(tetrahydro-2-furanyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 601518-38-1 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[2-[[2-(dimethylamino)ethyl]amino]-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]-7-methoxy-5-(tetrahydro-2-furanyl)-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 601518-39-2 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(5-amino-3,4-dihydro-2,6-naphthyridin-2(1H)-yl)-7-

10/ 040,319


methoxy-5-(tetrahydro-2-furanyl)-, trihydrochloride (9CI) (CA INDEX NAME)



●<sub>3</sub> HCl

RN 601518-40-5 CAPLUS

CN 4(1H)-Quinazolinone, 5-chloro-2-[7,8-dihydro-2-(1-pyrrolidinylmethyl)pyrido[4,3-d]pyrimidin-6(5H)-yl]-7-methoxy-, hydrochloride (9CI) (CA INDEX NAME)



●<sub>x</sub> HCl


RN 601518-41-6 CAPLUS

CN 4(1H)-Quinazolinone, 5-chloro-2-[3,4-dihydro-5-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl]-2,6-naphthyridin-2(1H)-yl]-7-methoxy-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/ 040,319




10/ 040,319




● 2 HCl

RN 601518-44-9 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-7-methoxy-5-(1-methyl-2-piperidinyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 601518-45-0 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-7-methoxy-5-(1-methyl-2-piperidinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 601518-46-1 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-6-[(2-methoxyethyl)amino]-2(1H)-isoquinolinyl]-7-methoxy-5-(1-methyl-2-piperidinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

10/ 040,319




● 3 HCl

RN 601518-47-2 CAPLUS  
 CN 4(1H)-Quinazolinone, 5-(butylsulfonyl)-2-[3,4-dihydro-5-[(2-methoxyethyl)amino]-2,6-naphthyridin-2(1H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 601518-48-3 CAPLUS  
 CN 4(1H)-Quinazolinone, 5-(butylsulfonyl)-2-[3,4-dihydro-5-[(2-pyridinylmethyl)amino]-2,6-naphthyridin-2(1H)-yl]-7-methoxy- (9CI) (CA INDEX NAME)




RN 601518-49-4 CAPLUS  
 CN 4(1H)-Quinazolinone, 7-methoxy-5-(1-methylethyl)-2-[1,4,6,7-tetrahydro-1-[2-(1-pyrrolidinyl)ethyl]-5H-pyrazolo[4,3-c]pyridin-5-yl]- (9CI) (CA INDEX NAME)

10/ 040,319




RN 601518-51-8 CAPLUS  
CN 4(1H)-Quinazolinone, 5-chloro-2-[3,4-dihydro-5-(1-pyrrolidinylmethyl)-2,6-naphthyridin-2(1H)-yl]-7-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 601518-52-9 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[7,8-dihydro-2-(4-methyl-1-piperazinyl)-1,6-naphthyridin-6(5H)-yl]-7-methoxy-5-(1-methylethyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 601518-53-0 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-[(methylamino)methyl]-2,6-naphthyridin-2(1H)-yl]-7-methoxy-5-(1-methylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

IT 601517-06-0P, [[6-(5-Isopropyl-7-methoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-5,6,7,8-tetrahydro-[1,6]naphthyridin-2-yl]methyl]carbamic acid tert-butyl ester 601517-10-6P, [[2-(5-Isopropyl-7-methoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-1,2,3,4-tetrahydroisoquinolin-5-yl]methyl]methylcarbamic acid tert-butyl ester  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of alkoxy quinazolinone compds. as  $\alpha$ 1L adrenoceptors antagonists useful in therapy)


RN 601517-06-0 CAPLUS

CN Carbamic acid, [[6-[1,4-dihydro-7-methoxy-5-(1-methylethyl)-4-oxo-2-quinazolinyl]-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 601517-10-6 CAPLUS

CN Carbamic acid, [[2-[1,4-dihydro-7-methoxy-5-(1-methylethyl)-4-oxo-2-quinazolinyl]-1,2,3,4-tetrahydro-5-isoquinolinyl]methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



## RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:637676 CAPLUS

DOCUMENT NUMBER: 137:185710

TITLE: Preparation of  $\beta$ -carbolines for pharmaceutical use as phosphodiesterase V inhibitors

INVENTOR(S): Sawyer, Jason Scott; Orme, Mark W.; Bombrun, Agnes; Bouilliot, Anne; Dodic, Nerina; Sierra, Michael; Gosmini, Roamin Luc Marie

PATENT ASSIGNEE(S): Lilly Icos LLC, USA

SOURCE: PCT Int. Appl., 155 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064590	A2	20020822	WO 2001-US49393	20011218
WO 2002064590	A3	20030227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1360185	A2	20031112	EP 2001-994320	20011218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2001-268158P	P 20010212
			WO 2001-US49393	W 20011218

OTHER SOURCE(S): MARPAT 137:185710  
GI

AB  $\beta$ -Carbolines, such as I [R = arylacyl, arylthioacyl, arylsulfonyl, etc.; R1 = Ph, substituted Ph, heteroaryl], were prepared for therapeutic use as phosphodiesterase V (PDE5) inhibitors in the treatment of conditions such as cardiovascular diseases, osteoporosis, sexual dysfunction, etc. Thus,  $\beta$ -carboline II was prepared in 75% yield by acylation of the corresponding unacylated  $\beta$ -carboline with 2-naphthalenecarbonyl chloride. The prepared  $\beta$ -carbolines were assayed

10/ 040,319

in vitro for inhibition of human PDE5 with II showing a 0.566  $\mu$ M IC50 value.


IT 449202-75-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of  $\beta$ -carbolines for pharmaceutical use as phosphodiesterase V inhibitors)

RN 449202-75-9 CAPLUS

CN 4(1H)-Quinazolinone, 2-[1-(1,3-benzodioxol-5-yl)-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)



L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:521731 CAPLUS

DOCUMENT NUMBER: 137:78966

TITLE: Preparation of substituted 3H-quinazolin-4-ones and 2H-benzo[1,2,4]thiadiazine-1,1-dioxides as alpha 1A/B adrenergic receptor antagonists for treatment of urinary tract disorders, sexual dysfunction, or pain

INVENTOR(S): Becker, Cyrus Kephra; Caroon, Jon Marie; Melville, Chris Richard; Padilla, Fernando; Pfister, Juerg Roland; Zhang, Xiaoming

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

*pregnant version*


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053558	A1	20020711	WO 2001-EP14885	20011217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2001016662	A	20030923	BR 2001-16662	20011217
EP 1363899	A1	20031126	EP 2001-985417	20011217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003069230	A1	20030410	US 2002-40319	20020102
PRIORITY APPLN. INFO.:				
			US 2001-259337P	P 20010102
			US 2001-325267P	P 20010927
			WO 2001-EP14885	W 20011217

OTHER SOURCE(S): MARPAT 137:78966

GI



I



II

AB Title compds. I [wherein X = C or N; Y = C; A = fused 5-6 membered (hetero)aromatic ring; Z = CO or SO<sub>2</sub>; R = alkyl; R<sub>1</sub> = H, alkyl, or (un)substituted aryl(alkyl) or arylaminocarbonyl; R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> = independently H, alkyl, hydroxy(alkyl), alkoxy(alkyl), halo(alkyl), cyano(alkyl), or (un)substituted cycloalkyl(alkyl), aryl(alkyl), heterocyclyl(alkyl), heteroaryl(alkyl), amino(alkyl), ureido, sulfamoyl, acyl, carbamoyl, etc.; or C<sub>2</sub>R<sub>2</sub>R<sub>3</sub> = (un)substituted (hetero)aryl; and isomers, pharmaceutically acceptable salts, or solvates thereof] were prepared as selective alpha-1A/B adrenoceptor antagonists. For example, 3-chloro-6,7-dimethoxy-2H-benzo[1,2,4]thiadiazine-1,1-dioxide and 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline were refluxed in methoxyethanol for 72 h to give II. In [3H]prazosin binding assays, the latter exhibited pK<sub>i</sub> values of 8.15, 8.79, and 7.18, resp., for binding toward α<sub>1</sub>A, α<sub>1</sub>B, and α<sub>1</sub>D adrenoceptor transfected CHO-K1 cells. Thus, I are useful for the treatment of urinary tract disorders and their symptoms, sexual dysfunction, or pain (no data). In addition, the subtype selectivity of I is expected to reduce the incidence of dose-limiting side effects, such as cardiovascular and CNS effects.

IT **441065-35-6P**, 2-(5-Hydroxymethyl-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxy-3H-quinazolin-4-one **441065-36-7P**, 2-(5-Bromomethyl-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxy-3H-quinazolin-4-one

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of quinazolinones and benzothiadiazines as α<sub>1</sub> adrenergic receptor antagonists for treatment of urinary tract disorders, sexual dysfunction, or pain)

RN 441065-35-6 CAPLUS


CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(hydroxymethyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)



10/ 040,319




RN 441065-36-7 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[5-(bromomethyl)-3,4-dihydro-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




IT **441064-40-0P**, 2-(5-Amino-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxy-3H-quinazolin-4-one **441065-61-8P**, 2-[5-[Imino(morpholin-4-yl)methyl]-3,4-dihydro-1H-isoquinolin-2-yl]-6,7-dimethoxy-3H-quinazolin-4-one  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
( $\alpha$ 1 adrenergic receptor antagonist; preparation of quinazolinones and benzothiadiazines as  $\alpha$ 1 adrenergic receptor antagonists for treatment of urinary tract disorders, sexual dysfunction, or pain)

RN 441064-40-0 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(5-amino-3,4-dihydro-2(1H)-isoquinolinyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 441065-61-8 CAPLUS  
CN Morpholine, 4-[[2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-5-isoquinolinyl]iminomethyl]- (9CI) (CA INDEX NAME)



IT **441064-35-3P**, 2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxy-1H-quinazolin-4-one **441064-36-4P**, 6,7-Dimethoxy-2-[5-(4-methoxyphenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-3H-quinazolin-4-one **441064-37-5P**, 2-(8-Fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxy-3H-quinazolin-4-one **441064-38-6P**, 2-(7,8-Dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-6-yl)-6,7-dimethoxy-3H-quinazolin-4-one **441064-39-7P**, 6,7-Dimethoxy-2-[7-(4-methoxyphenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-3H-quinazolin-4-one **441064-41-1P**, 6,7-Dimethoxy-2-[8-(4-methoxyphenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-3H-quinazolin-4-one **441064-42-2P**, 6,7-Dimethoxy-2-[5-(pyridin-3-yl)-3,4-dihydro-1H-isoquinolin-2-yl]-3H-quinazolin-4-one **441064-43-3P**, 6,7-Dimethoxy-2-[7-(pyrrolidin-1-yl)-3,4-dihydro-1H-isoquinolin-2-yl]-3H-quinazolin-4-one **441064-44-4P**, 6,7-Dimethoxy-2-[5-(pyrrolidin-1-yl)-3,4-dihydro-1H-isoquinolin-2-yl]-3H-quinazolin-4-one **441064-45-5P**, 2-(5,8-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxy-1H-quinazolin-4-one **441064-46-6P**, 6,7-Dimethoxy-2-(5-pyridin-4-yl-3,4-dihydro-1H-isoquinolin-2-yl)-3H-quinazolin-4-one **441064-47-7P**, 6,7-Dimethoxy-2-(5-pyrimidin-5-yl-3,4-dihydro-1H-isoquinolin-2-yl)-3H-quinazolin-4-one **441064-48-8P**, 2-(6,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-5-carbonitrile **441064-49-9P**, 6,7-Dimethoxy-2-[5-[1-(pyridin-3-yl)methanoyl]-3,4-dihydro-1H-isoquinolin-2-yl]-3H-quinazolin-4-one **441064-50-2P**, 6,7-Dimethoxy-2-[5-(1H-pyrrol-2-yl)-3,4-dihydro-1H-isoquinolin-2-yl]-3H-quinazolin-4-one **441064-51-3P**, 5-[2-(6,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-1,2,3,4-tetrahydroisoquinolin-5-yl]-1H-pyrimidine-2,4-dione **441064-52-4P**, 2-[5-(4,5-Dihydro-1H-imidazol-2-yl)-3,4-dihydro-1H-isoquinolin-2-yl]-6,7-dimethoxy-3H-quinazolin-4-one **441064-53-5P**, 2-[5-(1H-Imidazol-2-yl)-3,4-dihydro-1H-isoquinolin-2-yl]-6,7-dimethoxy-3H-quinazolin-4-one **441064-54-6P**, 6,7-Dimethoxy-2-[5-[1-(morpholin-4-yl)methanoyl]-3,4-dihydro-1H-isoquinolin-2-yl]-3H-quinazolin-4-one **441064-55-7P**, 6,7-Dimethoxy-2-[5-(pyridin-2-ylamino)-3,4-dihydro-1H-isoquinolin-2-yl]-1H-quinazolin-4-one **441064-56-8P**, 6,7-Dimethoxy-2-[5-(morpholin-4-yl)-3,4-dihydro-1H-isoquinolin-2-yl]-1H-quinazolin-4-one **441064-57-9P**, 6,7-Dimethoxy-2-(6-methoxy-3-methyl-3,4-dihydro-1H-isoquinolin-2-yl)-3H-quinazolin-4-one **441064-58-0P**, 2-(1-Isopropyl-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxy-3H-quinazolin-4-one **441064-59-1P**, 6,7-Dimethoxy-2-(4-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-1H-quinazolin-4-one **441064-60-4P**, 2-(1-Benzyl-6,7-difluoro-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxy-1H-quinazolin-4-one **441064-61-5P**, 2-[2-(6,7-Dimethoxy-4-oxo-1,4-dihydroquinazolin-2-yl)-1,2,3,4-tetrahydroisoquinolin-1-yl]-N-phenylacetamide **441064-62-6P**, 2-[7-Chloro-6-methoxy-1-[2-(p-tolyl)ethyl]-3,4-dihydro-1H-isoquinolin-2-yl]-6,7-dimethoxy-1H-quinazolin-4-one **441064-63-7P**, 2-(7-Chloro-6-methoxy-1-(p-tolyl)-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxy-1H-quinazolin-4-one **441064-64-8P**, 2-[7-Chloro-6-methoxy-1-[2-(pyridin-4-yl)ethyl]-3,4-

dihydro-1H-isoquinolin-2-yl]-6,7-dimethoxy-1H-quinazolin-4-one  
**441064-65-9P**, 2-(6,7-Dimethoxy-3-methyl-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxy-1H-quinazolin-4-one **441064-66-0P**,  
 2-(6,7-Dihydroxy-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxy-1H-quinazolin-4-one **441064-67-1P**, 2-[5-(2-Hydroxymethylphenyl)-3,4-dihydro-1H-isoquinolin-2-yl]-6,7-dimethoxy-3H-quinazolin-4-one  
**441064-68-2P**, 6,7-Dimethoxy-2-(1,3,4,9-tetrahydro- $\beta$ -carbolin-2-yl)-3H-quinazolin-4-one **441064-69-3P**, 6,7-Dimethoxy-2-(6-methoxy-1,3,4,9-tetrahydro- $\beta$ -carbolin-2-yl)-3H-quinazolin-4-one  
**441064-70-6P**, 6,7-Dimethoxy-2-(7-methylsulfanyl-1,3,4,9-tetrahydro- $\beta$ -carbolin-2-yl)-3H-quinazolin-4-one **441064-71-7P**,  
 2-(3,4-Dihydro-1H-2,7,10-triazaanthracen-2-yl)-6,7-dimethoxy-3H-quinazolin-4-one **441064-72-8P**, 2-(3,4-Dihydro-1H-[2,7]naphthyridin-2-yl)-6,7-dimethoxy-1H-quinazolin-4-one **441064-73-9P**,  
 6,7-Dimethoxy-2-[4-(morpholin-4-yl)-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl]-3H-quinazolin-4-one **441064-76-2P**, 2-(4-Benzylamino-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-6,7-dimethoxy-3H-quinazolin-4-one  
**441064-77-3P**, 6,7-Dimethoxy-2-[4-(4-methylpiperazin-1-yl)-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl]-3H-quinazolin-4-one  
**441064-78-4P**, 6,7-Dimethoxy-2-[4-[4-(2-methoxyphenyl)piperidin-1-yl]-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl]-3H-quinazolin-4-one  
**441064-79-5P**, 6,7-Dimethoxy-2-[4-[(2-methoxyethyl)methylamino]-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl]-3H-quinazolin-4-one **441064-80-8P**,  
 6,7-Dimethoxy-2-(4-piperidin-1-yl)-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl]-3H-quinazolin-4-one **441064-81-9P**,  
 2-[2-Isopropyl-4-(morpholin-4-yl)-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl]-6,7-dimethoxy-3H-quinazolin-4-one **441064-82-0P**,  
 6,7-Dimethoxy-2-[4-(6-methylpyridin-2-ylamino)-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl]-3H-quinazolin-4-one **441064-83-1P**,  
 2-[4-[(2-Hydroxyethyl)methylamino]-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl]-6,7-dimethoxy-3H-quinazolin-4-one **441064-84-2P**,  
 2-[4-(4-Hydroxypiperidin-1-yl)-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl]-6,7-dimethoxy-3H-quinazolin-4-one **441064-85-3P**,  
 6,7-Dimethoxy-2-[4-((S)-2-methoxymethylpyrrolidin-1-yl)-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl]-3H-quinazolin-4-one **441064-86-4P**,  
 2-[4-(2,6-Dimethylmorpholin-4-yl)-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl]-6,7-dimethoxy-3H-quinazolin-4-one **441064-87-5P**,  
 2-[4-(Hexylmethylamino)-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl]-6,7-dimethoxy-3H-quinazolin-4-one **441064-88-6P**, 6,7-Dimethoxy-2-[4-(pyrrolidin-1-yl)-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl]-3H-quinazolin-4-one **441065-02-7P** **441065-04-9P**,  
 6,7-Dimethoxy-2-[5-(morpholine-4-sulfonyl)-3,4-dihydro-1H-isoquinolin-2-yl]-3H-quinazolin-4-one **441065-06-1P**, 2-(6,7-Dimethoxy-4-oxo-1,4-dihydroquinazolin-2-yl)-1,2,3,4-tetrahydroisoquinoline-7-sulfonic acid  
 [2-(pyridin-2-yl)ethyl]amide **441065-07-2P**, 6,7-Dimethoxy-2-[7-(morpholine-4-sulfonyl)-3,4-dihydro-1H-isoquinolin-2-yl]-3H-quinazolin-4-one **441065-08-3P**,  
 2-(1-Benzyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-6,7-dimethoxy-3H-quinazolin-4-one **441065-09-4P**,  
 6,7-Dimethoxy-2-(1-(m-tolyl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-1H-quinazolin-4-one **441065-12-9P**, 6,7-Dimethoxy-2-(1-phenyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-3H-quinazolin-4-one  
**441065-13-0P**, 6,7-Dimethoxy-2-(3-phenyl-3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-3H-quinazolin-4-one  
**441065-14-1P**, 6,7-Dimethoxy-2-(1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-3H-quinazolin-4-one **441065-15-2P**,  
 6,7-Dimethoxy-2-[2-(1-phenylmethanoyl)-1,4,5,7-tetrahydropyrrolo[2,3-c]pyridin-6-yl]-3H-quinazolin-4-one **441065-16-3P**,  
 2-[1-(4-Chlorophenyl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]-6,7-dimethoxy-3H-quinazolin-4-one **441065-17-4P**, 6,7-Dimethoxy-2-[1-(naphthalen-2-yl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]-3H-quinazolin-4-one  
**441065-18-5P**, 6,7-Dimethoxy-2-[1-(4-methoxyphenyl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]-3H-quinazolin-4-one **441065-19-6P**, 2-[1-(2-Chlorophenyl)-1,4,6,7-

tetrahydroimidazo[4,5-c]pyridin-5-yl]-6,7-dimethoxy-3H-quinazolin-4-one  
**441065-20-9P**, 2-[1-(3-Chlorophenyl)-1,4,6,7-tetrahydroimidazo[4,5-  
 c]pyridin-5-yl]-6,7-dimethoxy-3H-quinazolin-4-one **441065-21-0P**,  
 6,7-Dimethoxy-2-[1-(3-trifluoromethylphenyl)-1,4,6,7-tetrahydroimidazo[4,5-  
 c]pyridin-5-yl]-3H-quinazolin-4-one **441065-22-1P**,  
 2-(1-Benzo[1,3]dioxol-5-yl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-  
 6,7-dimethoxy-3H-quinazolin-4-one **441065-23-2P**,  
 2-(1-Isobutyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)-6,7-dimethoxy-  
 1H-quinazolin-4-one **441065-24-3P**, 6,7-Dimethoxy-2-[1-(3-  
 methoxypropyl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]-1H-quinazolin-  
 4-one **441065-25-4P**, 2-(1-Cycloheptyl-1,4,6,7-  
 tetrahydroimidazo[4,5-c]pyridin-5-yl)-6,7-dimethoxy-1H-quinazolin-4-one  
**441065-26-5P**, 2-(1-sec-Butyl-1,4,6,7-tetrahydroimidazo[4,5-  
 c]pyridin-5-yl)-6,7-dimethoxy-1H-quinazolin-4-one **441065-27-6P**,  
 6,7-Dimethoxy-2-[1-(1-methylbutyl)-1,4,6,7-tetrahydroimidazo[4,5-d]pyridin-  
 5-yl]-1H-quinazolin-4-one **441065-28-7P**, 6,7-Dimethoxy-2-[1-(2-  
 methylbutyl)-1,4,6,7-tetrahydroimidazo[4,5-d]pyridin-5-yl]-1H-quinazolin-4-  
 one **441065-29-8P**, 2-(1-Cyclohexyl-1,4,6,7-tetrahydroimidazo[4,5-  
 c]pyridin-5-yl)-6,7-dimethoxy-1H-quinazolin-4-one **441065-30-1P**,  
 6,7-Dimethoxy-2-[1-(tetrahydrofuran-2-ylmethyl)-1,4,6,7-  
 tetrahydroimidazo[4,5-c]pyridin-5-yl]-1H-quinazolin-4-one  
**441065-31-2P**, 2-(1-Cyclopentyl-1,4,6,7-tetrahydroimidazo[4,5-  
 c]pyridin-5-yl)-6,7-dimethoxy-1H-quinazolin-4-one **441065-32-3P**  
**441065-38-9P 441065-40-3P 441065-42-5P**  
**441065-43-6P**, 6,7-Dimethoxy-2-[5-(piperidin-1-ylmethyl)-3,4-  
 dihydro-1H-isoquinolin-2-yl]-3H-quinazolin-4-one **441065-44-7P**  
**441065-46-9P 441065-47-0P**, [2-(6,7-Dimethoxy-4-oxo-3,4-  
 dihydroquinazolin-2-yl)-1,2,3,4-tetrahydroisoquinolin-5-yl]acetonitrile  
**441065-48-1P 441065-49-2P 441065-50-5P**,  
 N-[2-(6,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-1,2,3,4-  
 tetrahydroisoquinolin-5-yl]-4-methoxybenzamide **441065-51-6P**  
**441065-52-7P**, 2-[5-(4,5-Dihydro-1H-imidazol-2-ylamino)-3,4-dihydro-  
 1H-isoquinolin-2-yl]-6,7-dimethoxy-3H-quinazolin-4-one  
**441065-53-8P**, N-[2-(6,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-  
 yl)-1,2,3,4-tetrahydroisoquinolin-5-yl]isonicotinamide  
**441065-54-9P 441065-55-0P 441065-56-1P**,  
 N-[2-(6,7-Dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-1,2,3,4-  
 tetrahydroisoquinolin-5-yl]butyramide **441065-57-2P**  
**441065-58-3P 441065-59-4P**, 3-[2-[2-(6,7-Dimethoxy-4-oxo-  
 3,4-dihydroquinazolin-2-yl)-1,2,3,4-tetrahydroisoquinolin-5-  
 ylimino]pyrrolidin-1-yl]propionitrile **441065-60-7P**,  
 2-[5-(5,6-Dihydro-2H-[1,4]thiazin-3-ylamino)-3,4-dihydro-1H-isoquinolin-2-  
 yl]-6,7-dimethoxy-3H-quinazolin-4-one **441065-64-1P**  
**441065-65-2P**, 2-[5-(4-Aminopyridin-3-yl)-3,4-dihydro-1H-  
 isoquinolin-2-yl]-6,7-dimethoxy-3H-quinazolin-4-one **441065-69-6P**  
**441065-72-1P 441065-76-5P**, 6,7-Dimethoxy-2-[5-(morpholin-  
 4-ylmethyl)-3,4-dihydro-1H-isoquinolin-2-yl]-3H-quinazolin-4-one  
**441067-40-9P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

( $\alpha$ 1 adrenergic receptor antagonist; preparation of quinazolinones and  
 benzothiadiazines as  $\alpha$ 1 adrenergic receptor antagonists for  
 treatment of urinary tract disorders, sexual dysfunction, or pain)


RN 441064-35-3 CAPLUS

CN 4(1H)-Quinazolinone, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-  
 dimethoxy- (9CI) (CA INDEX NAME)


10/ 040,319




RN 441064-36-4 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(4-methoxyphenyl)-2(1H)-  
isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 441064-37-5 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(8-fluoro-3,4-dihydro-2(1H)-isoquinolinyl)-6,7-  
dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-38-6 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(7,8-dihydro-1,3-dioxolo[4,5-g]isoquinolin-6(5H)-  
yl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-39-7 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-7-(4-methoxyphenyl)-2(1H)-  
isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)

10/ 040,319




RN 441064-41-1 CAPLUS

CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-8-(4-methoxyphenyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-42-2 CAPLUS

CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(3-pyridinyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-43-3 CAPLUS

CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-7-(1-pyrrolidinyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-44-4 CAPLUS


CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(1-pyrrolidinyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-45-5 CAPLUS  
 CN 4(1H)-Quinazolinone, 2-(3,4-dihydro-5,8-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 441064-46-6 CAPLUS  
 CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(4-pyridinyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-47-7 CAPLUS  
 CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(5-pyrimidinyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-48-8 CAPLUS  
 CN 5-Isoquinolinecarbonitrile, 2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)


10/ 040,319




RN 441064-49-9 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(3-pyridinylcarbonyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 441064-50-2 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(1H-pyrrol-2-yl)-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 441064-51-3 CAPLUS  
CN 2,4(1H,3H)-Pyrimidinedione, 5-[2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-5-isoquinolinyl]- (9CI) (CA INDEX NAME)




RN 441064-52-4 CAPLUS




10/ 040,319

CN 4(1H)-Quinazolinone, 2-[5-(4,5-dihydro-1H-imidazol-2-yl)-3,4-dihydro-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-53-5 CAPLUS

CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(1H-imidazol-2-yl)-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 441064-54-6 CAPLUS


CN Morpholine, 4-[[2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-5-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 441064-55-7 CAPLUS

CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(2-pyridinylamino)-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)


10/ 040,319




RN 441064-56-8 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(4-morpholinyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 441064-57-9 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(3,4-dihydro-6-methoxy-3-methyl-2(1H)-isoquinolinyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-58-0 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-1-(1-methylethyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-59-1 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(3,4-dihydro-4-phenyl-2(1H)-isoquinolinyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)


10/ 040,319



RN 441064-60-4 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[6,7-difluoro-3,4-dihydro-1-(phenylmethyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-61-5 CAPLUS  
CN 1-Isoquinolineacetamide, 2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-N-phenyl- (9CI) (CA INDEX NAME)




RN 441064-62-6 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[7-chloro-3,4-dihydro-6-methoxy-1-[2-(4-methylphenyl)ethyl]-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)

10/ 040,319




RN 441064-63-7 CAPLUS

CN 4(1H)-Quinazolinone, 2-[7-chloro-3,4-dihydro-6-methoxy-1-(4-methylphenyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 441064-64-8 CAPLUS

CN 4(1H)-Quinazolinone, 2-[7-chloro-3,4-dihydro-6-methoxy-1-[2-(4-pyridinyl)ethyl]-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-65-9 CAPLUS

CN 4(1H)-Quinazolinone, 2-(3,4-dihydro-6,7-dimethoxy-3-methyl-2(1H)-


10/ 040,319

isoquinolinyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-66-0 CAPLUS

CN 4(1H)-Quinazolinone, 2-(3,4-dihydro-6,7-dihydroxy-1-methyl-2(1H)-isoquinolinyl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-67-1 CAPLUS

CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-[2-(hydroxymethyl)phenyl]-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 441064-68-2 CAPLUS


CN 4(1H)-Quinazolinone, 6,7-dimethoxy-2-(1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)- (9CI) (CA INDEX NAME)




RN 441064-69-3 CAPLUS

CN 4(1H)-Quinazolinone, 6,7-dimethoxy-2-(1,3,4,9-tetrahydro-6-methoxy-2H-pyrido[3,4-b]indol-2-yl)- (9CI) (CA INDEX NAME)


10/ 040,319




RN 441064-70-6 CAPLUS  
CN 4(1H)-Quinazolinone, 6,7-dimethoxy-2-[1,3,4,9-tetrahydro-7-(methylthio)-2H-pyrido[3,4-b]indol-2-yl]- (9CI) (CA INDEX NAME)




RN 441064-71-7 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(3,4-dihydropyrido[4,3-b][1,6]naphthyridin-2(1H)-yl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-72-8 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(3,4-dihydro-2,7-naphthyridin-2(1H)-yl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-73-9 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[5,8-dihydro-4-(4-morpholinyl)pyrido[3,4-d]pyrimidin-7(6H)-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 441064-76-2 CAPLUS  
 CN 4(1H)-Quinazolinone, 2-[5,8-dihydro-4-[(phenylmethyl)amino]pyrido[3,4-d]pyrimidin-7(6H)-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-77-3 CAPLUS  
 CN 4(1H)-Quinazolinone, 2-[5,8-dihydro-4-(4-methyl-1-piperazinyl)pyrido[3,4-d]pyrimidin-7(6H)-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-78-4 CAPLUS  
 CN 4(1H)-Quinazolinone, 2-[5,8-dihydro-4-[4-(2-methoxyphenyl)-1-piperidinyl]pyrido[3,4-d]pyrimidin-7(6H)-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)


10/ 040,319



RN 441064-79-5 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[5,8-dihydro-4-[(2-methoxyethyl)methylamino]pyrido[3,4-d]pyrimidin-7(6H)-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-80-8 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[5,8-dihydro-4-(1-piperidinyl)pyrido[3,4-d]pyrimidin-7(6H)-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-81-9 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[5,8-dihydro-2-(1-methylethyl)-4-(4-morpholinyl)pyrido[3,4-d]pyrimidin-7(6H)-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)



10/ 040,319




RN 441064-82-0 CAPLUS  
CN 4 (1H)-Quinazolinone, 2-[5,8-dihydro-4-[(6-methyl-2-pyridinyl)amino]pyrido[3,4-d]pyrimidin-7(6H)-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*

RN 441064-83-1 CAPLUS  
CN 4 (1H)-Quinazolinone, 2-[5,8-dihydro-4-[(2-hydroxyethyl)methylamino]pyrido[3,4-d]pyrimidin-7(6H)-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 441064-84-2 CAPLUS  
CN 4 (1H)-Quinazolinone, 2-[5,8-dihydro-4-(4-hydroxy-1-piperidinyl)pyrido[3,4-d]pyrimidin-7(6H)-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)


10/ 040,319



RN 441064-85-3 CAPLUS


CN 4(1H)-Quinazolinone, 2-[5,8-dihydro-4-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]pyrido[3,4-d]pyrimidin-7(6H)-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441064-86-4 CAPLUS


CN 4(1H)-Quinazolinone, 2-[4-(2,6-dimethyl-4-morpholinyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441064-87-5 CAPLUS

CN 4(1H)-Quinazolinone, 2-[4-(hexylmethylamino)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)


10/ 040,319



RN 441064-88-6 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[5,8-dihydro-4-(1-pyrrolidinyl)pyrido[3,4-d]pyrimidin-7(6H)-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441065-02-7 CAPLUS  
CN Piperazine, 1-[[2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-5-isoquinolinyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 441065-04-9 CAPLUS  
CN Morpholine, 4-[[2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-5-isoquinolinyl]sulfonyl]- (9CI) (CA INDEX NAME)

10/ 040,319




RN 441065-06-1 CAPLUS

CN 7-Isoquinolinesulfonamide, 2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 441065-07-2 CAPLUS

CN Morpholine, 4-[[2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-7-isoquinoliny]sulfonyl]- (9CI) (CA INDEX NAME)



RN 441065-08-3 CAPLUS


CN 4(1H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(phenylmethyl)-5H-imidazo[4,5-c]pyridin-5-yl]- (9CI) (CA INDEX NAME)




RN 441065-09-4 CAPLUS

CN 4(1H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(3-methylphenyl)-5H-imidazo[4,5-c]pyridin-5-yl]- (9CI) (CA INDEX NAME)


10/ 040,319




RN 441065-12-9 CAPLUS  
CN 4(1H)-Quinazolinone, 6,7-dimethoxy-2-(1,4,6,7-tetrahydro-1-phenyl-5H-imidazo[4,5-c]pyridin-5-yl)- (9CI) (CA INDEX NAME)



RN 441065-13-0 CAPLUS  
CN 4(1H)-Quinazolinone, 6,7-dimethoxy-2-(3,4,6,7-tetrahydro-3-phenyl-5H-imidazo[4,5-c]pyridin-5-yl)- (9CI) (CA INDEX NAME)




RN 441065-14-1 CAPLUS  
CN 4(1H)-Quinazolinone, 6,7-dimethoxy-2-(1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- (9CI) (CA INDEX NAME)




RN 441065-15-2 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(2-benzoyl-1,4,5,7-tetrahydro-6H-pyrrolo[2,3-c]pyridin-6-yl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)


10/ 040,319




RN 441065-16-3 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[1-(4-chlorophenyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 441065-17-4 CAPLUS  
CN 4(1H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(2-naphthalenyl)-5H-imidazo[4,5-c]pyridin-5-yl]- (9CI) (CA INDEX NAME)




RN 441065-18-5 CAPLUS  
CN 4(1H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(4-methoxyphenyl)-5H-imidazo[4,5-c]pyridin-5-yl]- (9CI) (CA INDEX NAME)




RN 441065-19-6 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[1-(2-chlorophenyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)


10/ 040,319




RN 441065-20-9 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[1-(3-chlorophenyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 441065-21-0 CAPLUS  
CN 4(1H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-[3-(trifluoromethyl)phenyl]-5H-imidazo[4,5-c]pyridin-5-yl]- (9CI) (CA INDEX NAME)




RN 441065-22-1 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[1-(1,3-benzodioxol-5-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441065-23-2 CAPLUS  
CN 4(1H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(2-methylpropyl)-5H-imidazo[4,5-c]pyridin-5-yl]- (9CI) (CA INDEX NAME)


10/ 040,319




RN 441065-24-3 CAPLUS  
CN 4(1H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(3-methoxypropyl)-5H-imidazo[4,5-c]pyridin-5-yl]- (9CI) (CA INDEX NAME)



RN 441065-25-4 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(1-cycloheptyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441065-26-5 CAPLUS  
CN 4(1H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(1-methylpropyl)-5H-imidazo[4,5-c]pyridin-5-yl]- (9CI) (CA INDEX NAME)




RN 441065-27-6 CAPLUS  
CN 4(1H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(1-methylbutyl)-5H-imidazo[4,5-c]pyridin-5-yl]- (9CI) (CA INDEX NAME)




10/ 040,319




RN 441065-28-7 CAPLUS  
CN 4(1H)-Quinazolinone, 6,7-dimethoxy-2-[1,4,6,7-tetrahydro-1-(2-methylbutyl)-5H-imidazo[4,5-c]pyridin-5-yl]- (9CI) (CA INDEX NAME)



RN 441065-29-8 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(1-cyclohexyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441065-30-1 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[(tetrahydro-2-furanyl)methyl]-5H-imidazo[4,5-c]pyridin-5-yl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441065-31-2 CAPLUS  
CN 4(1H)-Quinazolinone, 2-(1-cyclopentyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-6,7-dimethoxy- (9CI) (CA INDEX NAME)

10/ 040,319



RN 441065-32-3 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(4-morpholinylmethyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 441065-38-9 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-[[2-(hydroxymethyl)-1-pyrrolidinyl]methyl]-2(1H)-isoquinolinyl]-6,7-dimethoxy-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441065-37-8  
CMF C25 H30 N4 O4

Absolute stereochemistry.




10/ 040,319

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441065-40-3 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-[(4-methyl-1-piperazinyl)methyl]-2(1H)-isoquinolinyl]-6,7-dimethoxy-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 441065-39-0


CMF C25 H31 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441065-42-5 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-[[4-(hydroxymethyl)-1-piperidinyl]methyl]-2(1H)-isoquinolinyl]-6,7-dimethoxy-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441065-41-4

CMF C26 H32 N4 O4


10/ 040,319




CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 441065-43-6 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(1-piperidinylmethyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441065-44-7 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(1-piperidinylmethyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 441065-43-6


CMF C25 H30 N4 O3

10/ 040,319



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 441065-46-9 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-[(4-hydroxy-1-piperidyl)methyl]-  
2(1H)-isoquinolinyl]-6,7-dimethoxy-, trifluoroacetate (salt) (9CI) (CA  
INDEX NAME)

CM 1


CRN 441065-45-8  
CMF C25 H30 N4 O4




CM 2

CRN 76-05-1  
CMF C2 H F3 O2


10/ 040,319



RN 441065-47-0 CAPLUS  
CN 5-Isoquinolineacetonitrile, 2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 441065-48-1 CAPLUS  
CN Methanimidamide, N'-[2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-5-isoquinolinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 441065-49-2 CAPLUS  
CN Methanimidamide, N'-[2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-5-isoquinolinyl]-N,N-dimethyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 441065-48-1  
CMF C22 H25 N5 O3




CM 2

10/ 040,319


CRN 76-05-1  
CMF C2 H F3 O2



RN 441065-50-5 CAPLUS  
CN Benzenecarboximidamide, N-[2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-5-isoquinolinyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 441065-51-6 CAPLUS  
CN Cyclopentanecarboximidamide, N-[2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-5-isoquinolinyl]- (9CI) (CA INDEX NAME)




RN 441065-52-7 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[5-[(4,5-dihydro-1H-imidazol-2-yl)amino]-3,4-dihydro-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)


10/ 040,319



RN 441065-53-8 CAPLUS  
CN 4-Pyridinecarboximidamide, N-[2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-5-isoquinolinyl]- (9CI) (CA INDEX NAME)




RN 441065-54-9 CAPLUS  
CN 2-Furancarboximidamide, N-[2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-5-isoquinolinyl]- (9CI) (CA INDEX NAME)




RN 441065-55-0 CAPLUS  
CN Cyclobutanecarboximidamide, N-[2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-5-isoquinolinyl]- (9CI) (CA INDEX NAME)




10/ 040,319




RN 441065-56-1 CAPLUS  
CN Butanimidamide, N-[2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-5-isoquinolinyl]- (9CI) (CA INDEX NAME)




RN 441065-57-2 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[5-[(4,5-dihydro-1-methyl-1H-pyrrol-2-yl)amino]-3,4-dihydro-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441065-58-3 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[5-[(4,5-dihydro-1H-pyrrol-2-yl)amino]-3,4-dihydro-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 441065-59-4 CAPLUS  
CN 1-Pyrrolidinepropanenitrile, 2-[[2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-5-isoquinolinyl]imino]- (9CI) (CA INDEX NAME)




RN 441065-60-7 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[5-[(5,6-dihydro-2H-1,4-thiazin-3-yl)amino]-3,4-dihydro-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441065-64-1 CAPLUS  
CN Morpholine, 4-[[2-(1,4-dihydro-6,7-dimethoxy-4-oxo-2-quinazolinyl)-1,2,3,4-tetrahydro-5-isoquinolinyl]iminomethyl]-, hydrochloride (9CI) (CA INDEX NAME)

10/ 040,319




•x HCl

RN 441065-65-2 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[5-(4-amino-3-pyridinyl)-3,4-dihydro-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441065-69-6 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(4-morpholinyl)-2,6-naphthyridin-2(1H)-yl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 441065-72-1 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[5-(4-amino-3-pyridinyl)-3,4-dihydro-2(1H)-isoquinolinyl]-6,7-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)

10/ 040,319




● x HCl

RN 441065-76-5 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-(4-morpholinylmethyl)-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 441067-40-9 CAPLUS  
CN 4(1H)-Quinazolinone, 2-[3,4-dihydro-5-[(3,4,5,6-tetrahydro-2-pyridinyl)amino]-2(1H)-isoquinolinyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:16:54 ON 23 MAY 2004)

FILE 'REGISTRY' ENTERED AT 15:17:40 ON 23 MAY 2004